| scholarly article | Q13442814 |
| P2093 | author name string | D Morgan | |
| D Turbitt | |||
| G Lloyd | |||
| A Kitching | |||
| T Brooks | |||
| J Coakley | |||
| S Cathcart | |||
| M Nicholas | |||
| D Krahé | |||
| S Addiman | |||
| L Bischop | |||
| P433 | issue | 6 | |
| P921 | main subject | Lassa fever | Q706845 |
| Lassa virus | Q1806636 | ||
| P304 | page(s) | 854-858 | |
| P577 | publication date | 2009-02-12 | |
| P1433 | published in | Eurosurveillance | Q14565070 |
| P1476 | title | A fatal case of Lassa fever in London, January 2009 | |
| P478 | volume | 14 |
| Q92664092 | A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks-results from the Lassa fever pilot |
| Q62240884 | A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation |
| Q55246727 | Absence of Nosocomial Transmission of Imported Lassa Fever during Use of Standard Barrier Nursing Methods. |
| Q33870918 | Acute abdominal pain in patients with lassa fever: Radiological assessment and diagnostic challenges |
| Q26823627 | Advanced vaccine candidates for Lassa fever |
| Q40156113 | Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines |
| Q35770348 | Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report |
| Q97421769 | Compliance with disease surveillance and notification by private health providers in South-West Nigeria |
| Q39608675 | Conserved residues in Lassa fever virus Z protein modulate viral infectivity at the level of the ribonucleoprotein |
| Q33621077 | Constraints in the diagnosis and treatment of Lassa Fever and the effect on mortality in hospitalized children and women with obstetric conditions in a rural district hospital in Sierra Leone |
| Q41919417 | Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016. |
| Q30224036 | Diagnostic issues and capabilities in 48 isolation facilities in 16 European countries: data from EuroNHID surveys. |
| Q30209669 | Diagnostic proficiency and reporting of Lassa fever by physicians in Osun State of Nigeria |
| Q64246765 | Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings |
| Q27928040 | Diagnostics in Ebola Virus Disease in Resource-Rich and Resource-Limited Settings |
| Q40349669 | Early-onset sensorineural hearing loss in Lassa fever. |
| Q35870592 | Evaluation of Lassa antiviral compound ST-193 in a guinea pig model |
| Q34057974 | Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness. |
| Q95275894 | Exploring Lassa Virus Proteome to Design a Multi-epitope Vaccine Through Immunoinformatics and Immune Simulation Analyses |
| Q41922424 | Expression and X-Ray Structural Determination of the Nucleoprotein of Lassa Fever Virus |
| Q37503583 | Facing the threat of highly infectious diseases in Europe: the need for a networking approach |
| Q52590886 | Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. |
| Q34484140 | Guidance for contact tracing of cases of Lassa fever, Ebola or Marburg haemorrhagic fever on an airplane: results of a European expert consultation |
| Q40076535 | Imported Case of Lassa Fever in Sweden With Encephalopathy and Sensorineural Hearing Deficit |
| Q35645720 | Imported Lassa fever: A report of 2 cases in Ghana |
| Q34414498 | Isolation facilities for highly infectious diseases in Europe--a cross-sectional analysis in 16 countries |
| Q51333133 | Lassa fever: another threat from West Africa. |
| Q43161212 | Lassa fever: the challenges of curtailing a deadly disease. |
| Q28744660 | Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report |
| Q41919409 | Lessons learnt from imported cases and onward transmission of Lassa fever in Europe support broader management of viral haemorrhagic fevers |
| Q41929865 | Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers |
| Q34645925 | Multifunctional nature of the arenavirus RING finger protein Z. |
| Q35014564 | Pathogenesis of Lassa fever in cynomolgus macaques |
| Q37766010 | Reassessing the risk from rabies: a continuing threat to the UK? |
| Q36037694 | Retrospective evaluation of control measures for contacts of patient with Marburg hemorrhagic fever |
| Q38388959 | Specialized clinical facilities for the treatment of highly contagious, life-threatening infectious diseases : a comparison between Germany and 15 European nations |
| Q30227579 | The European network of Biosafety-Level-4 laboratories: enhancing European preparedness for new health threats. |
| Q36381649 | The risk of transmission of a viral haemorrhagic fever infection in a United Kingdom laboratory |
| Q30210429 | Transportation capacity for patients with highly infectious diseases in Europe: A survey in 16 nations |
| Q34888593 | Using modelling to disentangle the relative contributions of zoonotic and anthroponotic transmission: the case of lassa fever |
Search more.